<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525704</url>
  </required_header>
  <id_info>
    <org_study_id>AVDR 2018-01 v1.2</org_study_id>
    <nct_id>NCT03525704</nct_id>
  </id_info>
  <brief_title>Evaluation of Contact Lens Saline Solutions With Scleral GP Contact Lens Wearers Experiencing Fogging</brief_title>
  <official_title>Evaluation of Contact Lens Saline Solutions With Scleral GP Contact Lens Wearers Experiencing Fogging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contamac Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Andre Vision and Device Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Contact Lens Center at Optique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Premiere Vision Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Havasu Eye Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Contamac Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of saline solutions used with scleral rigid gas permeable contact lens wearers&#xD;
      experiencing debris in the post lens tear reservoir&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One-month, approximately 36 subjects enrolled (~12/site), randomized, double-masked crossover&#xD;
      trial.&#xD;
&#xD;
      Existing scleral rigid gas permeable (RGP) contact lens wearing subjects are randomly&#xD;
      assigned (block) to different arms of the trial and receive different saline solutions for&#xD;
      use sequentially for 2-week periods. The subjects will continue to wear their existing&#xD;
      scleral GP lenses if lens fit is acceptable following an initial evaluation. Subjects will&#xD;
      agree to complete a survey administered daily (via email) that will address contact lens wear&#xD;
      time and subjective symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">December 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>One-month, approximately 36 subjects enrolled (~12/site), randomized, double-masked crossover trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized, Double-Masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Subjective Symptoms and Wear Time Survey</measure>
    <time_frame>1 Month</time_frame>
    <description>Participant Survey on Lens Comfort (based on a scale of 0 to 5), Symptoms (graded based on frequency (rarely/sometimes/often/always) and severity(slight/moderate/severe)), Total Wear Time (reported as hours per day) and How Many Times Lenses are Removed Daily (reported as number of times per day)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomicroscopy Findings</measure>
    <time_frame>1 Month</time_frame>
    <description>Edema, Bulbar Redness, Limbal Redness, Corneal Vascularization, Corneal Infiltrates, Palpebral Conjunctival Observations and Corneal Staining are evaluated on a grading scale of 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 Month</time_frame>
    <description>Visual acuity (in units of Logmar) is evaluated with subject wearing habitual contact lenses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Contact Lens Complication</condition>
  <condition>Debris in Post Lens Tear Reservoir</condition>
  <arm_group>
    <arm_group_label>Saline Solution Enriched</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline Solution enriched with electrolytes and PH balanced to mimic normal tears</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Rinse Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline Solution .9% NaCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline Solution Enriched</intervention_name>
    <description>Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution</description>
    <arm_group_label>Saline Solution Enriched</arm_group_label>
    <other_name>NutriFill</other_name>
    <other_name>GatorFill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline Rinse Solution</intervention_name>
    <description>sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i</description>
    <arm_group_label>Saline Rinse Solution</arm_group_label>
    <other_name>LacriPure</other_name>
    <other_name>ScleralFil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:â€¢&#xD;
&#xD;
          -  Daily wear large diameter (scleral) rigid gas permeable contact lens wearers in design&#xD;
             with acceptable fit&#xD;
&#xD;
          -  18 years old or above.&#xD;
&#xD;
          -  Agree to and sign Informed Consent.&#xD;
&#xD;
          -  Correctable to at least 20/40 distance visual acuity in each eye.&#xD;
&#xD;
          -  Presence of debris or &quot;fogging&quot; in post lens tear film reservoir (PLTR).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extended wear contact lens wearers&#xD;
&#xD;
          -  Require concurrent ocular medication.&#xD;
&#xD;
          -  Grade 2 or more slit lamp findings (does not include fogging assessment).&#xD;
&#xD;
          -  Eye injury or surgery within twelve weeks immediately prior to enrolment for this&#xD;
             trial.&#xD;
&#xD;
          -  Currently enrolled in an ophthalmic clinical trial.&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Evidence of active ophthalmic disease or abnormality including glaucoma,&#xD;
             chorioretinitis, central retinal artery or vein occlusion, intraocular or ocular&#xD;
             infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bret Andre, MS, ABOe</last_name>
    <role>Study Director</role>
    <affiliation>AVD Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andre Vision and Device Research</name>
      <address>
        <city>West Linn</city>
        <state>Oregon</state>
        <zip>97068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fogging</keyword>
  <keyword>Insertion Solutions</keyword>
  <keyword>RGP</keyword>
  <keyword>Scleral</keyword>
  <keyword>Contact Lenses</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

